Does vitamin e cure nonalcoholic steatohepatitis?

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 2, 2011, Pages 147-150

  Adinolfi, Luigi E ^a   Restivo, Luciano ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

NAFLD; NASH; oxidative stress; vitamin E

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; ASCORBIC ACID; ATORVASTATIN; PIOGLITAZONE; PLACEBO; TRANSFORMING GROWTH FACTOR BETA1; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIOXIDANT ACTIVITY; DISEASE COURSE; DRUG FATALITY; DRUG MEGADOSE; EDITORIAL; EXERCISE; HISTOPATHOLOGY; HUMAN; LIPID PEROXIDATION; LIVER BIOPSY; LIVER FIBROSIS; LOW CALORY DIET; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; RISK FACTOR; WEIGHT REDUCTION;

DIETARY SUPPLEMENTS; FATTY LIVER; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN E;

EID: 79954494227     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.11.27     Document Type: Editorial

References (34)

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43(Suppl. 1), S99-S103 (2006).
2. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population based cohort study Gastroenterology 129, 113-121 (2005). (Pubitemid 41002048)
3. Patel AA, Torres DM, Harrison SA. Effect of weight loss on nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 43, 970-974 (2009).
4. Ratziu V, Zelber-Sagi S. Pharmacologic therapy of non-alcoholic steatohepatitis. Clin. Liver Dis. 13, 667-688 (2009)
5. Musso G, Gambino R, Cassader M et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 52(1), 79-104 (2010).
6. Weltman MD, Farrell GC, Hall P et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology. 27, 128-133 (1998). (Pubitemid 28041545)
7. Sanyal AJ, Campbell-Sargeant C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 120, 1183-1192 (2001). (Pubitemid 32246672)
8. Chalasani N, Gorski JC, Asghar MS et al. Hepatic cytochrome P450 2E1 activity in non-diabetic patients with non-alcoholic steatohepatitis. Hepatology. 37, 544-550 (2003). (Pubitemid 36258775)
9. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99, 1497-1502 (2004). (Pubitemid 39193189)
10. Phung N, Pera N, Farrell G et al. Pro-oxidant-mediated hepatic fbrosis and effects of antioxidant intervention in murine dietary steatohepatitis. Int. J. Mol. Med. 24, 171-180 (2009).
11. Brigelius-Flohé R. Vitamin E: the shrew waiting to be tamed. Free Radic. Biol. Med. 46, 543-554 (2009).
12. Ban R, Takitani K, Kim HS et al. a-tocopherol transfer protein expression in rat liver exposed to hyperoxia. Free Radic Res. 36, 933-938 (2002). (Pubitemid 34863640)
13. Fechner H, Schlame M, Guthmann F et al. a-and ô-tocopherol induce expression of hepatic a-tocopherol-transfer-protein mRNA. Biochem. J. 331, 577-581 (1998).
14. Shaw HM, Huang CJ. Liver a-tocopherol transfer protein and its mRNA are differentially altered by dietary vitamin E defciency and protein insuffciency in rat. J. Nutr. 128, 2348-2354 (1998).
15. Sies H, Stahl W, Sundquist AR. Antioxidant functions of vitamins. Vitamins E and C, ß-carotene, and other carotenoids. Ann. NY Acad. Sci. 669, 7-20 (1992). (Pubitemid 23009923)
16. Chang CY, Argo CK, Al-Osaimi AM et al. Therapy of NAFLD: antioxidants and cytoprotective agents. J. Clin. Gastroenterol. 40(Suppl. 1), S51-S60 (2006). (Pubitemid 44309544)
17. Parola M, Muraca R, Dianzani I et al. Vitamin E dietary supplementation inhibits tissue growth factor ß-1 gene expression in the rat liver. FEBS Lett. 308, 267-270 (1992).
18. Fang F, Kang Z, Wong C. Vitamin E tocotrienols improve insulin sensitivity though activating peroxome proliferators-activated receptors. Mol. Nutr. Food Res. 54, 345-352 (2010).
19. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for non alcoholic steatohepatitis. N. Engl. J. Med. 362(18), 1675-1685 (2010).
20. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J. Pediatr. 136, 734-738 (2000). (Pubitemid 30415645)
21. Hasegawa T, Yoneda M, Nakamura K et al. Plasma transforming growth factor-ß1 level and effcacy of a-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study Aliment. Pharmacol. Ther. 15, 1667-1672 (2001). (Pubitemid 32912411)
22. Vajro P, Mandato C, Franzese A et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study J. Pediatr. Gastroenterol. Nutr. 38, 48-55 (2004). (Pubitemid 39274467)
23. Kugelmas M, Hill DB, Vivian B et al. Cytokines and NASH: a pilot study of the effects of lifestyle modifcation and vitamin E. Hepatology 38, 413-419 (2003). (Pubitemid 36919862)
24. Lavine JE, Schwimmer JB, Molleston JP et al. Vitamin E, metformin or placebo for treatment of nonalcoholic fatty liver disease in children. Hepatology 52, 374A-375A (2010).
25. Sanyal AJ, Mofrad PS, Contos MJ et al. A pilot study of vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2, 1107-1115 (2004). (Pubitemid 40037642)
26. Harrison SA, Torgerson S, Hayashi P et al. Vitamin E and vitamin C treatment improves fbrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 98, 2485-2490 (2003). (Pubitemid 37448761)
27. Dufour JF, Oneta CM, Gonvers JJ et al. Randomized placebo-controlled trial of ursodesoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 4, 1537-1543 (2006). (Pubitemid 44880031)
28. Foster T, Budoff M, Saab S et al. Atorvastatin and antioxidants for the treatment of non alcoholic fatty liver disease: the St Francis heart study randomized clinical trial. Am. J. Gastroenterol. 106, 71-77 (2010).
29. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 128(1), 24-32 (2005). (Pubitemid 40039955)
30. Klatsky AL, Morton C, Udaltsova N et al. Coffee, cirrhosis, and transaminase enzymes. Arch. Intern. Med. 166(11), 1190-1195 (2006). (Pubitemid 43877627)
31. Miller ER III, Pastor-Barriuso R, Dalal D et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 142, 37-46 (2005).
32. Dietrich M, Jacques PF, Pencina MJ et al. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: does the underlying health status play a role? Atherosclerosis 205, 549-553 (2009).
33. Maras JE, Bermudez OI, Qiao N et al. Intake ofα-tocopherol is limited among US adults. J. Am. Diet. Assoc. 104, 567-575 (2004).
34. Schleicher RL, Carroll MD, Ford ES et al. Serum vitamin C and the prevalence of vitamin C defciency in the United States: 2003-2004 National Health and Nutrition Examination Survey (NHANES). Am. J. Clin. Nutr. 90, 1252-1263 (2009).